Please Wait...

Regulatory Expertise

Led by tenured senior executives with extensive clinical research experience, Bioclinica's global cardiac safety and efficacy regulatory expertise is second to none. Bioclinica's unmatched regulatory leadership is well recognized and backed by ongoing professional relationships with key authorities and panels. We have worked with the ICH and FDA to advance industry standards and guidance in the conduct of TQT studies and have successfully completed the first ever regulatory mandated TQT studies in both Japan and China. Bioclinica has supported the design and specific cardiac monitoring technology for our sponsors on studies requested by regulatory authorities. The data from such studies has met the predefined goals established by both sponsor and regulatory organizations.

Bioclinica's regulatory services include:

  • Protocol consultation and guidance throughout development life cycle
  • Fast-tracked ECG and imaging data regulatory submissions and archiving
  • Audit preparation and support
  • FDA ECG warehouse submission
  • Integrated Cardiac Safety Summary reports in support of the alternative approach to formal TQT study requirements

Industry Associations

Bioclinica continues to accelerate drug development, working in tandem with regulatory bodies and key clinical research associations to establish and maintain core lab industry standards for cardiac safety services.

Our contributions include interaction with the following:

  • Metrics Champion Consortium (MCC)
  • Cardiac Safety Research Consortium (CSRC)
  • International CardioOncology Society (ICOS)
  • ICH-E14 expert advisory panel
  • American Society of Hypertension (ASH)
  • American Telemedicine Association (ATA)
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

https://t.co/UZQTot9ovJ
bioclinica (13 hours ago)
RT @Xtalks: When is Central Imaging Needed in #ClinicalTrials? @bioclinica https://t.co/fYGvqU46TI
bioclinica (13 hours ago)
RT @phillytechnews: 11/7: BioClinica, USA Technologies buy California firms ; First Round names female general partner https://t.co/MAvm6…
bioclinica (13 hours ago)
RT @eClinical_Jen: Content from the FDA Webinar on Study Data Technical Conformance Guidelines is here: https://t.co/14eepSOR7b #ITTX17
bioclinica (13 hours ago)
RT @CenterWatch: .@US_FDA approves first #digital pill with sensor to track #patients adherence, https://t.co/XaEctKIFRx
bioclinica (13 hours ago)
RT @RAPSorg: Could you use a mid-week laugh? Many #regulatory pros will appreciate this one, courtesy of @CharlesTam https://t.co/8WxeftiCPv
bioclinica (14 hours ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices